ライフサイエンスコーパス: MRA

1 MRA escape leads to false-negative genetic interaction r

2 MRA for screening followed by carbon dioxide angiography

3 MRA index, % wall volume, and ankle-brachial index corre

4 MRA was also used to evaluate patient 15 but was unsucce

5 MRAs reduce the risk of SCD in patients with left ventri

6 in the ACR 20% response between the other 3 MRA cohorts and placebo at week 2.

7 ry disease (CAD) underwent free-breathing 3D MRA with and without T2prep and with 120- and 60-ms data

8 suspected venous anomalies were imaged by 3D MRA.

9 ed all patients who underwent Gd-enhanced 3D MRA examination from January 1998 through January 2001,

10 Gadolinium-enhanced 3D MRA is a fast and accurate technique for delineation of

11 Gadolinium-enhanced 3D MRA is a fast magnetic resonance imaging technique that

12 Gadolinium-enhanced 3D MRA is capable of rapidly and accurately diagnosing a wi

13 In 74% of patients, 3D MRA either diagnosed previously unsuspected venous anoma

14 The 3D MRA diagnoses were followed by 10 interventional cathete

15 r CAI; sensitivities were 53% (CTA) and 47% (MRA) for VAI.

16 Furthermore, patients with abnormal MRA findings and higher TCD velocities are at higher ris

17 ard care arm, 4 of 13 patients with abnormal MRA findings had strokes compared with 5 of 40 patients

18 In the 7 days after MRA initiation among patients who remained alive and out

19 se are at high risk for adverse events after MRA initiation.

20 ction is common, laboratory monitoring after MRA initiation frequently does not meet guideline recomm

21 nd creatinine (Cr) before and serially after MRA initiation, but the extent to which this occurs is u

22 -alpha treatment, the promising alternatives MRA, abatacept, and rituximab have been tested.

23 Although MRA has been shown to be more cost effective and to have

24 Initial ambulatory MRA dispensing occurred at hospital discharge in 70.0% o

25 Among MRA-treated patients with symptomatic HFrEF, severe hype

26 An MRA temporal-superior sector outside normal limits had a

27 Ucn2 and an MRA (canrenoic acid [CA]) were infused for 4 hours, both

28 ally having healthy neuroretinal rims and an MRA analysis of within normal limits in all sectors.

29 tions of acute administration of Ucn2 and an MRA in experimental HF.

30 with short-term adjunct Ucn2 therapy and an MRA in HF.

31 neficiaries with heart failure started on an MRA, 19.7% were initiated during a hospitalization.

32 We randomized 1,603 patients to receive an MRA regimen with a single intravenous bolus of potassium

33 d participants [21.6% female]) not taking an MRA at baseline, the 4671 patients (55.6% [22.0% female]

34 Among those taking an MRA at baseline, the overall rates of hyperkalemia were

35 71 patients (55.6% [22.0% female]) taking an MRA tended to be younger, with a lower EF, lower systoli

36 mong patients treated or not treated with an MRA at baseline and the risk of subsequent hyperkalemia

37 hyperkalemia for those newly treated with an MRA during study follow-up were defined in time-updated

38 Ucn2 cotreatment with an MRA in HF further improved hemodynamics relative to that

39 GPS) and the Moorfields Regression Analysis (MRA) for discriminating between glaucomatous and healthy

40 The overall Moorfields regression analysis (MRA) result from the HRT was used as a separate diagnost

41 nd HRT-based Moorfields Regression Analysis (MRA) results of outside normal limits in any sector.

42 Moorfields Regression Analysis (MRA) with CLST was performed globally and sectorally to

43 PS), the HRT Moorfields regression analysis (MRA), scanning laser polarimetry (GDx enhanced corneal c

44 ion of MRA is less than histologic analysis, MRA-obtained vascular attributes provide useful informat

45 EGFR phosphorylation in coronary artery and MRA dysfunction in diabetic db/db mice.

46 ice with AG1478 improved coronary artery and MRA endothelial function and restored eNOS expression.

47 Cohort B: 9 patients had BOLD and MRA data.

48 Overall reported sensitivity for CTA and MRA (TCD is poorer) was 76-98% and specificity was 85-10

49 CTA and MRA are much poorer methods for the detection of aneurys

50 Although CTA and MRA can detect some proximal moderate to severe arterial

51 Follow-up CTA and MRA were assessed for persistent arterial occlusion or r

52 Comparison of CTA and MRA with cerebral angiography in 143 patients demonstrat

53 less-invasive diagnostic techniques (CTA and MRA) are inadequate for screening.

54 lts suggest that in this population, GPS and MRA differentiate between glaucomatous and healthy eyes

55 Likelihood ratios for regional GPS and MRA results outside normal limits ranged from 4.0 to 10.

56 e on the diagnostic accuracy of both GPS and MRA was evaluated using the generalized estimating equat

57 mproved diagnostic accuracy for both GPS and MRA.

58 ociated with the sensitivity of both GPS and MRA.

59 Combining 3D MRI and MRA is effective for quantitatively characterizing CTEV

60 nance brain imaging and angiography (MRI and MRA) at exit showed no new cerebral infarcts in either t

61 OP, 232 brain magnetic resonance angiograms (MRAs) were performed on 100 patients, 47 in the transfus

62 ical CT angiography (CTA) or MR angiography (MRA) for live renal donor evaluation is still controvers

63 ing coronary magnetic resonance angiography (MRA) allows for submillimeter image resolution but suffe

64 ance imaging/magnetic resonance angiography (MRA) and transcranial Doppler (TCD) exams were performed

65 are coronary magnetic resonance angiography (MRA) and x-ray coronary angiography findings in patients

66 -enhanced 3D magnetic resonance angiography (MRA) can provide a noninvasive alternative to diagnostic

67 Magnetic resonance angiography (MRA) demonstrated tight stenoses in the common iliac art

68 Based on MRI/magnetic resonance angiography (MRA) findings, infarct size, and location, 36 patients w

69 of coronary magnetic resonance angiography (MRA) for assessing human epicardial coronary artery vaso

70 re recently, magnetic resonance angiography (MRA) has been compared with conventional angiography.

71 ghted and 3D magnetic resonance angiography (MRA) images were acquired.

72 culopathy by magnetic resonance angiography (MRA) in children with hemoglobin SS, the most serious fo

73 nsional (3D) magnetic resonance angiography (MRA) in patients with congenital and acquired anomalies

74 the value of magnetic resonance angiography (MRA) in the follow-up of patients with autosomal dominan

75 Magnetic resonance angiography (MRA) offers a noninvasive, complementary approach that p

76 ng (MRI) and magnetic resonance angiography (MRA) studies, a neurologic examination by a pediatric ne

77 ng (MRI) and magnetic resonance angiography (MRA) within 6 months of initial imaging.

78 tomography, magnetic resonance angiography (MRA), and noncontrast MRA are each of limited use becaus

79 ests such as magnetic resonance angiography (MRA), computed tomographic angiography (CTA) and transcr

80 and cervical magnetic resonance angiography (MRA), could also be risk factors for SCI.

81 ing coronary magnetic resonance angiography (MRA), coverage of the coronary artery tree may be limite

82 MRI, magnetic resonance angiography (MRA), Doppler ultrasound, CT, and positron emission tomo

83 onal flow on magnetic resonance angiography (MRA), quantitative MRA, and high-resolution MRI of the a

84 ts underwent magnetic resonance angiography (MRA), treadmill testing with maximal oxygen consumption

85 -dimensional magnetic resonance angiography (MRA).

86 While need for receptor antagonist (MRA) MRA after diagnosis suggests that a defined daily d

87 ith a mineralocorticoid receptor antagonist (MRA).

88 reatments such as interleukin-6 antagonists (MRA), CTLA4Ig (abatacept), and anti-B cell therapy (ritu

89 Mineralocorticoid receptor antagonists (MRA) improve outcome in the setting of post-myocardial i

90 Mineralocorticoid receptor antagonists (MRA) reduce morbidity and mortality in heart failure wit

91 BB), mineralocorticoid receptor antagonists (MRA), and angiotensin receptor-neprilysin inhibitors (AR

92 e of mineralocorticoid receptor antagonists (MRAs) for selected patients with symptomatic heart failu

93 Mineralocorticoid receptor antagonists (MRAs) have become established therapy in heart failure (

94 Mineralocorticoid receptor antagonists (MRAs) may attenuate this risk.

95 The mineralocorticoid receptor antagonists (MRAs) spironolactone and eplerenone have proved valuable

96 kinra), antiinterleukin-6 receptor antibody (MRA), and rituximab (anti-CD20 monoclonal antibody) are

97 y used mouse mesenteric resistance arteries (MRAs) to investigate the role of EGFR transactivation un

98 ary artery and mesenteric resistance artery (MRA) were mounted in an arteriograph.

99 ated non-invasive imaging modalities such as MRA (Magnetic Resonance Angiography) and renal angiograp

100 a congener-specific mixture risk assessment (MRA) of human exposure to combinations of BDE-209 and ot

101 lection is mating-type-regulated auxotrophy (MRA), by which prototrophy is restricted to a particular

102 Baseline MRA findings were interpreted as normal in 75 patients a

103 ents with normal or mildly abnormal baseline MRA but remained abnormal in 8 of 10 patients with sever

104 10 patients with severely abnormal baseline MRA.

105 is suggested that the combination of ACEI+BB+MRA was associated with a 56% reduction in mortality ver

106 The combination of ARNI+BB+MRA resulted in the greatest mortality reduction.

107 4, 95% credible interval 0.26-0.66); ARNI+BB+MRA was associated with the greatest reduction in all-ca

108 is showed that treatment with ACEI, ARB, BB, MRA, and ARNI and their combinations were better than th

109 In the 30 days before MRA initiation, 94.3% of patients had a K or Cr measurem

110 Although laboratory monitoring before MRA initiation for heart failure with reduced ejection f

111 normalities indicative of stroke risk before MRA lesions become evident.

112 Outcomes included laboratory testing before MRA initiation and in the early (days 1-10) and extended

113 There was complete agreement between MRA and x-ray angiography in the detection of CAA (n=11)

114 The mean difference between MRA and catheterization measurements of 33 pulmonary ves

115 m width (BMO-MRW); and minimum rim area (BMO-MRA) optimized within sectors and then summed.

116 tor-wise optimized BMO-minimum rim area (BMO-MRA).

117 to differentiate glaucoma was 0.873 for BMO-MRA, compared to 0.866 for BMO-gMRA (P = 0.004).

118 Global and temporal inferior BMO-MRA performed best in differentiating glaucoma patients.

119 jacency constraint within calculation of BMO-MRA does not improve diagnostic power.

120 MD was better correlated with BMO-MRA (r = 0.534) or BMO-MRW (r = 0.546) than with either

121 NFL thickness was better correlated with BMO-MRA (r = 0.676) or BMO-MRW (r = 0.680) than with either

122 , range: 1 day to 46.9 years) underwent both MRA and cardiac catheterization (median time: 1 month).

123 by both modalities, and patients abnormal by MRA often were abnormal by MRI (p < 0.00001).

124 tomatic concurrent aneurysm were detected by MRA in this study in 18 patients from 15 families.

125 pression in eight patients was determined by MRA but not by other imaging modalities.

126 vasculature properties can be determined by MRA.

127 Three additional APCs were diagnosed by MRA but not by catheterization.

128 ry veins that were subsequently diagnosed by MRA.

129 catheterization were correctly diagnosed by MRA.

130 patients with suspected APVs were studied by MRA after inconclusive assessment by catheterization, TE

131 ot reveal additional aneurysms undetected by MRA.

132 ic resonance imaging/MRA, including cervical MRA at the last assessment.

133 to diagnostic catheterization and to compare MRA and x-ray angiography measurements of pulmonary arte

134 Coronary MRA demonstrated a 23% increase in cross-sectional area

135 Coronary MRA may provide an alternative noninvasive method to dir

136 Free-breathing 3D coronary MRA accurately defines CAA in patients with Kawasaki dis

137 Free-breathing, T2prep, 3D coronary MRA with a shorter acquisition window resulted in improv

138 ng navigator-gated and corrected 3D coronary MRA.

139 blique submillimeter free-breathing coronary MRA allows depiction of extensive parts of the native co

140 Comparing coronary MRA and X-ray angiography, a good agreement of anatomy a

141 Nitroglycerin-enhanced coronary MRA can noninvasively measure coronary artery vasodilati

142 f 75 days (range, 1 to 359 days) of coronary MRA.

143 High-resolution multi-slice spiral coronary MRA (in-plane resolution of 0.52 to 0.75 mm) was perform

144 CAA from Kawasaki disease underwent coronary MRA using a free-breathing T2-prepared 3D bright blood s

145 ospective multicenter studies where coronary MRA is compared with X-ray angiography.

146 udy sought to assess the benefit of an early MRA regimen in acute MI irrespective of the presence of

147 he study failed to show the benefit of early MRA use in addition to standard therapy in patients admi

148 st, three-dimensional, spoiled gradient-echo MRA with surgical findings in 15 living renal donors.

149 Eight MRA studies were obtained in the three patients with sym

150 and basilar stenosis using contrast-enhanced MRA in consecutive patients, irrespective of age, presen

151 MRI with three-dimensional contrast-enhanced MRA provides rapid and comprehensive anatomic definition

152 dentified who underwent ferumoxytol-enhanced MRA after a nondiagnostic ultrasound for kidney dysfunct

153 Our study suggests that ferumoxytol-enhanced MRA may be a novel, safe method to accurately detect gra

154 We have found the gadolinium-enhanced MRA technique to be 100% accurate and as reliable as con

155 This study represents the first MRA analysis of a spontaneous preclinical brain tumor mo

156 -resolution three-dimensional time-of-flight MRA sequences at 3 T.

157 In addition, average patient charge for MRA was compared with that of conventional angiogram.

158 ce of a critical and descriminating role for MRA.

159 Using a five-level grading system for MRA image quality (1 = nondiagnostic; 5 = excellent), th

160 Furthermore, MRAs attenuate the appearance of secondary hyperparathyr

161 The combined approach of 3D-Gd-MRA and PC-flow revealed the best (P = 0.0003) interobse

162 3D-Gd-MRA revealed a slightly improved interobserver variabili

163 ery ostium was significantly better in 3D-Gd-MRA than in DSA, whereas the visibility of the hilar and

164 y (DSA), 3D-Gadolinium MR angiography (3D-Gd-MRA), cine phase-contrast flow measurement (PC-flow), an

165 Cohort A: 31 patients had MRA, DSC-PWI and BOLD data.

166 Modifications engineered to reduce haploid MRA escape reduced false negative results in SGA-type an

167 actly half as many eyes were abnormal by HRT MRA.

168 severe glaucoma, sensitivity increased: HRT MRA, HRT GPS, and OCT would miss 5% of eyes, and GDx wou

169 The HRT MRA had the highest sensitivity (87.0%; 95% confidence i

170 When the HRT MRA was used as the diagnostic standard, sensitivities o

171 e and retention by the F98 rat glioma, human MRA melanoma, and murine L929 cell lines, all of which a

172 longitudinally by magnetic resonance imaging/MRA, including cervical MRA at the last assessment.

173 ssure-induced myogenic tone was increased in MRA and coronary artery from diabetic mice and normalize

174 art failure as of July 1, 2011, and incident MRA use between May 1 and September 30, 2011.

175 Isolated MRAs were mounted in an arteriograph and stimulated by 2

176 tly lower than those in the 0.1- and 1-mg/kg MRA and the placebo cohorts (6.4, 6.2, and 7.0, respecti

177 es fell significantly in the 5- and 10-mg/kg MRA cohorts and normalized 2 weeks after treatment.

178 ients in the placebo, 0.1-, 1-, and 10-mg/kg MRA cohorts).

179 s in the placebo, 0.1-, 1-, 5-, and 10-mg/kg MRA cohorts, respectively) required corticosteroid or di

180 ve interval between the initial and the last MRA was 306 months (mean, 30.6; range, 14 to 51 months).

181 tive interval between the first and the last MRA was 95 months (mean, 31.7; range, 15 to 49 months).

182 Mean MRA index of number and severity of stenoses was 0.84 +/

183 ge cultures from human metastatic melanomas (MRA cells) results in increased apoptosis and decreased

184 e deleterious mutations in this microregion (MRA) of UGT1A1 in CN-I patients are evidence of a critic

185 While need for receptor antagonist (MRA) MRA after diagnosis suggests that a defined daily dose (

186 magnetic resonance imaging/angiography (MRI/MRA) findings into large-vessel (LV) versus small-vessel

187 may decrease mortality for patients needing MRA.

188 at least 1 year of transfusions, and have no MRA-defined severe vasculopathy, hydroxycarbamide treatm

189 resonance angiography (MRA), and noncontrast MRA are each of limited use because of technical factors

190 s compared with 5 of 40 patients with normal MRA findings (P=.03).

191 enosis compared with 28 patients with normal MRA findings or mild stenosis (276.7 +/- 34 vs 215 +/- 1

192 A novel MRA vasculopathy grading scale demonstrated frequent sev

193 h catheterization and surgical observations, MRA had a 100% sensitivity and specificity for the diagn

194 in subacute stroke patients who had obvious MRA lesions with sparse collaterals, those with abundant

195 The remaining 16 patients without obvious MRA lesions showed neither TTP nor TSA time delay.

196 Spironolactone accounted for 99.4% of MRA use.

197 esponse to shear stress and acetylcholine of MRA and coronary artery from diabetic mice was altered a

198 Quantitative analysis of MRA images of spontaneous preclinical tumor models has n

199 suggests that a defined daily dose (DDD) of MRA between 12.5 and 50 mg may alleviate risk of death i

200 cidental ICA, and the rate of development of MRA-defined de novo ICA in these patients.

201 nt and prescription of appropriate dosage of MRA for PA patients.

202 pathophysiologic basis for the inclusion of MRA in the overall management of these disorders and the

203 fference was observed between the 5 mg/kg of MRA and placebo, with 5 patients (55.6%) in the MRA coho

204 ous dose of either 0.1, 1, 5, or 10 mg/kg of MRA or placebo.

205 n those who received 5 mg/kg and 10 mg/kg of MRA was 4.8 and 4.7 (P < 0.001 and P < 0.001 by analysis

206 d smooth muscle cell EGFR phosphorylation of MRA and coronary artery from diabetic mouse, which was r

207 essel count, and the average vessel radii of MRA-visible vessels within the tumor.

208 the most appropriate therapeutic regimen of MRA in RA.

209 Although the spatial resolution of MRA is less than histologic analysis, MRA-obtained vascu

210 Although the spatial resolution of MRA prohibits visualization of capillaries, a high densi

211 ar intracranial aneurysms (ICA), the risk of MRA-defined growth of asymptomatic incidental ICA, and t

212 Median age at time of MRA initiation was 73 years, and 37.1% were women.

213 mprovement efforts that encourage the use of MRA should also include mechanisms to address recommende

214 is meta-analysis was to assess the impact of MRAs on SCD in patients with left ventricular systolic d

215 Comparative effectiveness studies of MRAs on SCD in usual care as well as studies evaluating

216 risk of hyperkalemia associated with use of MRAs for patients with HFrEF is reduced by sacubitril/va

217 morbidity and mortality; however, the use of MRAs in combination with other inhibitors of the renin-a

218 Use of MRAs was encouraged but left to the discretion of study

219 Patients initiated on MRA therapy as an outpatient had extremely poor rates of

220 fraction who were subsequently initiated on MRA therapy.

221 to prevent SCD in patients receiving optimal MRA therapy are needed to guide clinical decision-making

222 We are concerned that CTA or MRA may overlook mild cases of DSA-detectable FMD.

223 ic resonance angiography (MRA), quantitative MRA, and high-resolution MRI of the atherosclerotic plaq

224 nd its attendant risks in patients receiving MRAs.

225 This work identified factors that reduce MRA escape, including insertion of terminator and repres

226 Standard MRA criteria were used to identify arterial tortuousity

227 In 13 of 16 subjects, MRA demonstrated normal graft vasculature, and an altern

228 In 2 of 16 subjects, MRA detected moderate to severe anastomotic stenoses, wh

229 In 1 of 16 subjects, MRA with ferumoxytol demonstrated complete arterial occl

230 including patients who newly started taking MRAs during the PARADIGM-HF trial, severe hyperkalemia r

231 ecificities and lower likelihood ratios than MRA.

232 These results indicate that MRA is an appropriate technique to follow small asymptom

233 The MRA compares measured rim area with predicted rim area a

234 The MRA measurements had low interobserver variability (< or

235 The MRA was evaluated at baseline (Heidelberg Retina Tomogra

236 est boron uptake was seen with N7-2OH by the MRA 27 melanoma and L929 wild-type (wt) cell lines.

237 All eyes classified as "borderline" by the MRA were assigned to the normal category (i.e., "within

238 and placebo, with 5 patients (55.6%) in the MRA cohort and none in the placebo cohort achieving ACR

239 erior and temporal-superior positions of the MRA are highly predictive for the onset of visual field

240 ator and repressor sequences upstream of the MRA cassette, deletion of silent mating-type loci, and u

241 sensitivity and specificity (95% CI) of the MRA result were 66.7% (58.0%-76.1%) and 88.7% (78.5%-94.

242 HR (for onset of visual field losses) of the MRA temporal-inferior sector outside normal limits was 3

243 accessory renal artery was suggested on the MRA but was not detected by conventional angiography.

244 ostic data available for comparison with the MRA findings.

245 Thirty MRA studies were obtained in 10 of the 15 patients with

246 tory results and adverse events proximate to MRA initiation.

247 n fraction of </=45%, randomized subjects to MRAs versus control and reported outcomes on SCD, total

248 stitutional experience with renal transplant MRA using ferumoxytol (a nonnephrotoxic medication) as a

249 utilization of alpha-type instead of a-type MRA.

250 d patients during this same period underwent MRA.

251 ion attenuates the risk of hyperkalemia when MRAs are combined with other inhibitors of the renin-ang

252 useful for confirming a normal disc, whereas MRA may be most helpful in confirming a suspicion of gla

253 Patients treated with MRAs had 23% lower odds of experiencing SCD compared wit